Status
Conditions
About
Background:
Objectives:
Eligibility:
Design:
Full description
Objectives:
The proposed clinical trial will investigate the role of the human genome including genetic variations and gene expression profiles on the development of phantom limb pain (PLP).
Study population:
Patients will be recruited from military personnel with major limb amputations. A total of one thousand subjects with upper or lower extremity amputations of any level will be enrolled in this study.
Design:
Eight hundred subjects with chronic PLP (PLP patient) and 200 patients without PLP (non-PLP patient) will assess the severity of their pain symptom. Each participant will undergo a routine blood draw from which DNA and RNA will be harvested.
Outcome measures:
Using Affymetrix SNP 6.0 technology, which identifies up to 1 million single nucleotide polymorphisms (SNPs) and 1 million copy number variations in the human genome, the differences in genomic variations between the PLP and the non-PLP patients will be analyzed. An extreme subset of PLP patients will be tested for their quantitative sensory function and profiled gene expression and epigenetic pattern with the Affymetrix Human Exon ST 1.0 and Illumina Genome Analyzer IIx. These integrative genomic analyses using genetic variations, gene expression and epigenetic profile could explain why some amputees experience chronic PLP and some do not. By studying these responses in patient samples, we will evaluate the role of genomic factors in PLP. SNP frequencies, gene expression and epigenetic profiles between PLP and non-PLP groups will be analyzed.
Sex
Ages
Volunteers
Inclusion and exclusion criteria
PLP GROUP:
NON PLP GROUP:
-same with PLP group except:
--Experienced PLP less than 10 times total and/or for less than two weeks
EXCLUSION CRITERIA:
BOTH PLP AND NON-PLP GROUPS:
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal